AaviGen — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

AaviGen is a private, pre-clinical stage biotech developing next-generation, organ-specific gene therapies for heart failure. Its core asset is the 'next-CAP' platform, which enables the creation of proprietary AAV vectors with high cardiac specificity and an improved safety profile by minimizing off-target effects. Led by a team with deep expertise in cardiology and gene therapy development, including founder Prof. Patrick Most who previously founded and sold InoCard to uniQure, the company is building a pipeline to address the significant unmet medical need in heart failure, a condition affecting over 64 million patients worldwide with high mortality. AaviGen is currently pre-revenue and focused on R&D.

CardiovascularHeart Failure

Technology Platform

Proprietary 'next-CAP' platform for engineering novel, organ-specific Adeno-Associated Viral (AAV) vectors with high specificity for the heart, designed to enable safe and precise gene delivery.

Opportunities

The massive, growing global heart failure patient population (64M+) represents a multi-billion dollar market with severe unmet need and high mortality.

AaviGen's organ-specific vector platform, if successfully validated, could overcome key safety barriers that have limited broader application of gene therapy, enabling a transformative, one-time treatment paradigm for a chronic, debilitating disease.

Risk Factors

Key risks include the high scientific and technical challenge of proving the efficacy and unparalleled safety of a novel AAV platform in humans, the intense competition in heart failure therapeutics from large pharma, and total dependence on external financing as a pre-revenue, pre-clinical company facing a long and costly development path.

Competitive Landscape

The cardiac gene therapy space is competitive, featuring large biopharma companies (e.g., Pfizer, Bayer) and biotechs (e.g., Tenaya Therapeutics, Rocket Pharmaceuticals) pursuing various genetic targets and delivery methods. AaviGen's differentiation hinges on its claimed next-generation, heart-specific AAV capsids designed for superior safety, competing against earlier-generation, less specific vectors used by others.

More companies in Cell & Gene Therapy →More companies in Germany →